News

Enlarge image

BusinessIreland

Test predicts good MS prognosis

12.03.2013 - Elan and Biogen Idec have presented a new test at AAN meeting which identifies JCV infected MS patients with good prognosis.

Whilst Tysabri (natalizumab) is the most effective treatment for relapsing multiple sclerosis, it has also its downsides: the antibody drug increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study presented at the American Academy of Neurology's 65th Annual Meeting in San Diego suggests that early detection of PML may help improve survival and disability levels of MS patients.  

In the study, which was conducted by Irish Elan and Biogen Idec, 319 MS patients were treated with natalizumab and diagnosed with PML. The study compared people who had symptoms of PML at the time of diagnosis to people who had no symptoms of the infection, but who were diagnosed with the disease by brain scans and tests in the spinal fluid for the JC virus. The level of disability for the people in the study was assessed before the PML diagnosis, at the time of diagnosis, and again six months and one year after the diagnosis.  

A total of 21 people had no PML symptoms at the time of their diagnosis, while 298 people did. According to preliminary findings, people without symptoms at diagnosis showed improved survival and less disability than those who had developed symptoms. As of January 1, 2013, all of the 21 people (100%) with no symptoms at the time of PML diagnosis were alive, compared to 77% of the people with symptoms at the time of diagnosis. "These results suggest that the consequences of PML infection can be mitigated by early detection of the disease," said lead investigator Dong-Si.  

In mid-February, US biotech Biogen Idec had bagged full rights to Elan's Multiple Sclerosis blockbuster Tysabri in a US$3.25bn deal. Shortly after the agreement, US investor Royalty Pharma made a take-over bid but the Irish drugmaker is fighting off a possible take-over.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/test-finds-people-with-good-ms-prognosis.html

CommercialisationEU

10.02.2016 In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.05 CHF25.00%
  • ZEALAND PHARMA (DK)105.50 DKK14.05%
  • SARTORIUS (D)244.45 EUR12.88%

FLOP

  • PAION (D)1.25 EUR-36.55%
  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%

TOP

  • VERONA PHARMA (UK)3.30 GBP26.9%
  • IXICO (UK)35.75 GBP21.2%
  • SAREUM HOLDINGS (UK)0.30 GBP20.0%

FLOP

  • BIONOR PHARMA (N)0.81 NOK-50.6%
  • PAION (D)1.25 EUR-49.4%
  • PROTHENA PLC (IE)31.97 USD-38.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.50 SEK3123.7%
  • NICOX (F)6.80 EUR241.7%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.65 SEK-86.2%
  • BIOTEST (D)13.40 EUR-85.7%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 11.02.2016